Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) may protect against vertebral fractures in people with diabetes, ...

Glucagon-like peptide-1 receptor agonist therapy is associated with a reduced risk for epilepsy in adults with type 2 diabetes mellitus.

Type 2 diabetes is a recognized risk factor for vertebral fractures, which can lead to long-term disability and increased ...

References i Zhu D., Zhao J., Cai H., et al. Mazdutide versus placebo in Chinese adults with type 2 diabetes. Nature (2025). doi: 10.1038/s41586-025-10026-w ii ...

A systematic review and meta-analysis evaluated the risk for obesity-related cancer associated with glucagon-like peptide-1 ...

For patients with type 2 diabetes, there is an association between glucagon-like peptide-1 receptor agonist (GLP-1 RA) use and chronic cough, according to a study published online Nov. 26 in JAMA ...

The use of GLP-1 receptor agonists (GLP-1 RAs) was associated with a lower risk for serious infections — particularly respiratory, skin and soft tissue, musculoskeletal, and vascular infections as ...

GLP-1 receptor agonists may reduce glaucoma risk in T2D patients, though the reduction was nonsignificant. The review included five high-quality observational studies with over 2.5 million ...

GLP-1 RAs probably have little or no effect on risk for thyroid cancer, pancreatic cancer, breast cancer, or kidney cancer.

GLP-1RAs improved RA disease activity, pain scores, weight, cholesterol, and HbA1c levels in patients with a BMI ≥27. Nearly one-third of patients discontinued GLP-1RA therapy due to gastrointestinal ...

Use of SGLT2 inhibitors rather than GLP-1 receptor agonists is associated with lower risk of progression to kidney replacement therapy among patients with type 2 diabetes and CKD. The risk of ...

Anti-obesity drugs such as semaglutide (Ozempic, Wegovy) are also promising for the treatment of alcohol use disorder and alcohol-associated liver disease, as growing evidence suggests they reduce the ...